ANATOMIC PEEK PTC Cervical Fusion System
Device Facts
| Record ID | K160528 |
|---|---|
| Device Name | ANATOMIC PEEK PTC Cervical Fusion System |
| Applicant | Medtronic Sofamor Danek USA, Inc. |
| Product Code | ODP · Orthopedic |
| Decision Date | Mar 28, 2016 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 888.3080 |
| Device Class | Class 2 |
| Attributes | Therapeutic, Real-World Evidence |
Real-World Evidence
| Submission | Device | Sponsor | RWD Sources | RWE Use Summary | Key Tags |
|---|---|---|---|---|---|
| K160528 · Mar 28, 2016 | ANATOMIC PEEK PTC Cervical Fusion System | Medtronic Sofamor Danek USA, Inc. | Published clinical literature | A comprehensive literature review was provided to support the substantial equivalence of the subject device by demonstrating clinical performance consistent with the predicate devices. | Literature review; Clinical performance; Substantial equivalence |
Clinical Evidence
| Study Design | Population | Comparator | Key Endpoints |
|---|---|---|---|
| Comprehensive literature review; Literature review | Patients with degenerative disc disease (DDD) of the cervical spine | Not applicable for this study | Clinical performance/substantial equivalence |
Indications for Use
The ANATOMIC PEEK™ PTC Cervical Fusion System is indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one disc level or two contiguous levels. DDD is defined as discogenic pain with degeneration of the disc confirmed by patient history and radiographic studies. The ANATOMIC PEEK™ PTC Cervical Fusion System is used to facilitate intervertebral body fusion in the cervical spine and is placed via an anterior approach from the C2-C3 disc space using autograft or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft. The ANATOMIC PEEK™ PTC Cervical Fusion System is to be used with supplemental fixation. Patients should have at least six weeks of non-operative treatment prior to treatment with an intervertebral cage.
Device Story
Cervical interbody fusion device; hemi-cylindrical cage design; implanted via anterior approach (C2-T1). Input: autogenous or allogenic bone graft (cancellous/corticocancellous) packed into hollow cage geometry. Function: provides structural support and stabilization to facilitate intervertebral fusion. Used by surgeons in clinical settings. Output: physical stabilization of cervical disc space. Benefit: facilitates fusion in DDD patients; reduces discogenic pain. Requires supplemental fixation.
Clinical Evidence
Clinical evidence provided via comprehensive literature review. No new clinical trials conducted; substantial equivalence supported by literature and performance data.
Technological Characteristics
Materials: PEEK OPTIMA, commercially pure titanium coating, tantalum markers. Form factor: Hemi-cylindrical cages of varying widths, heights, and depths. Principle: Intervertebral body fusion via anterior approach. Energy source: None (mechanical). Connectivity: None. Sterilization: Not specified.
Indications for Use
Indicated for skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with radicular symptoms at one or two contiguous levels. Requires at least six weeks of prior non-operative treatment. Contraindicated in patients without skeletal maturity or those not requiring supplemental fixation.
Regulatory Classification
Identification
An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.
Special Controls
*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.